Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: RYN001
MIFTS: 40

Raynaud Disease

Categories: Cardiovascular diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Raynaud Disease

About this section

MalaCards integrated aliases for Raynaud Disease:

Name: Raynaud Disease 57 12 44 15 73
Raynaud's Disease 12 43
Secondary Raynaud's Phenomenon 73
Cold Fingers, Hereditary 57
Raynaud's Syndrome 12
Raynaud Phenomenon 73

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
raynaud disease:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

OMIM 57 179600
Disease Ontology 12 DOID:10300
ICD10 33 I73.0
MeSH 44 D011928
MedGen 42 C0034734
SNOMED-CT via HPO 69 263681008 266261006
Sources

Summaries for Raynaud Disease

About this section
MedlinePlus : 43 Raynaud's disease is a rare disorder of the blood vessels, usually in the fingers and toes. It causes the blood vessels to narrow when you are cold or feeling stressed. When this happens, blood can't get to the surface of the skin and the affected areas turn white and blue. When the blood flow returns, the skin turns red and throbs or tingles. In severe cases, loss of blood flow can cause sores or tissue death. Primary Raynaud's happens on its own. The cause is not known. There is also secondary Raynaud's, which is caused by injuries, other diseases, or certain medicines. People in colder climates are more likely to develop Raynaud's. It is also more common in women, people with a family history, and those over age 30. Treatment for Raynaud's may include drugs to keep the blood vessels open. There are also simple things you can do yourself, such as Soaking hands in warm water at the first sign of an attack Keeping your hands and feet warm in cold weather Avoiding triggers, such as certain medicines and stress NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Raynaud Disease, also known as raynaud's disease, is related to raynaud phenomenon and reynolds syndrome, and has symptoms including abdominal pain, angina pectoris and chest pain. An important gene associated with Raynaud Disease is RCC1 (Regulator Of Chromosome Condensation 1), and among its related pathways/superpathways are Platelet Aggregation Inhibitor Pathway, Pharmacodynamics and Endothelin Pathways. The drugs Cilostazol and Platelet Aggregation Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and heart, and related phenotypes are abnormality of the skeletal system and raynaud phenomenon

Description from OMIM: 179600
Sources

Related Diseases for Raynaud Disease

About this section

Diseases related to Raynaud Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 17)
# Related Disease Score Top Affiliating Genes
1 raynaud phenomenon 31.7 EDN1 VWF
2 reynolds syndrome 11.2
3 diffuse scleroderma 10.2 EDN1 TOP1
4 scleroderma, familial progressive 10.2 EDN1 TOP1
5 eisenmenger syndrome 10.1 EDN1 VWF
6 angina pectoris 10.0 EDN1 VWF
7 diabetic angiopathy 10.0 EDN1 VWF
8 hepatopulmonary syndrome 10.0 EDN1 VWF
9 rheumatic disease 9.9 IL1R1 TOP1
10 limb ischemia 9.9 EDN1 VWF
11 portal hypertension 9.8 EDN1 VWF
12 chronic pulmonary heart disease 9.8 EDN1 PTGIR
13 arteries, anomalies of 9.6 EDN1 VWF
14 diabetes mellitus 9.6
15 systemic scleroderma 9.5 EDN1 TOP1
16 collagen disease 9.5 EDN1 TOP1 VWF
17 pulmonary hypertension 9.0 EDN1 PTGIR VWF

Graphical network of the top 20 diseases related to Raynaud Disease:



Diseases related to Raynaud Disease
Sources

Symptoms & Phenotypes for Raynaud Disease

About this section

Symptoms via clinical synopsis from OMIM:

57
Limbs:
intermittent attacks of numb and white fingers


Clinical features from OMIM:

179600

Human phenotypes related to Raynaud Disease:

32
# Description HPO Frequency HPO Source Accession
1 abnormality of the skeletal system 32 HP:0000924
2 raynaud phenomenon 32 HP:0030880

UMLS symptoms related to Raynaud Disease:


abdominal pain, angina pectoris, chest pain, cold intolerance, constipation, coughing, diarrhea, dyspepsia, edema, fatigue, fever, halitosis, headache, heartburn, icterus, nausea and vomiting, pain, pelvic pain, pruritus, sciatica, syncope, chronic pain, vertigo/dizziness, gastrointestinal gas, symptoms, joint or joint related complaint

MGI Mouse Phenotypes related to Raynaud Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.17 ACOT7 CHST8 EDN1 IL1R1 PEPD PTGIR
Sources

Drugs & Therapeutics for Raynaud Disease

About this section

Drugs for Raynaud Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
2 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
3 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
4 Anti-Asthmatic Agents Phase 4
5 Autonomic Agents Phase 4,Early Phase 1
6 Bronchodilator Agents Phase 4
7 Fibrinolytic Agents Phase 4
8 Neuroprotective Agents Phase 4,Early Phase 1
9 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
10 Phosphodiesterase 3 Inhibitors Phase 4
11 Phosphodiesterase Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
12 Protective Agents Phase 4,Early Phase 1
13 Respiratory System Agents Phase 4
14
Nitroglycerin Approved, Investigational Phase 3,Phase 2,Phase 1 55-63-0 4510
15
Acetylcholine Approved Phase 3,Phase 2,Not Applicable 51-84-3 187
16
Tadalafil Approved, Investigational Phase 3,Phase 2,Not Applicable 171596-29-5 110635
17
Iloprost Approved, Investigational Phase 3 78919-13-8 6443959
18
Nifedipine Approved Phase 3,Early Phase 1 21829-25-4 4485
19
Amlodipine Approved Phase 2, Phase 3 88150-42-9 2162
20
Udenafil Approved, Investigational Phase 2, Phase 3 268203-93-6 6918523
21
Bupivacaine Approved, Investigational Phase 2, Phase 3 2180-92-9, 38396-39-3 2474
22
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
23
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 3,Early Phase 1 77-92-9 311
24 Fasudil Investigational Phase 3 103745-39-7
25 Antihypertensive Agents Phase 2, Phase 3,Not Applicable,Early Phase 1
26 abobotulinumtoxinA Phase 3,Phase 2,Not Applicable
27 Botulinum Toxins Phase 3,Phase 2,Not Applicable
28 Botulinum Toxins, Type A Phase 3,Phase 2,Not Applicable
29 Cholinergic Agents Phase 3,Phase 2,Not Applicable
30 insulin Phase 3
31 Insulin, Globin Zinc Phase 3
32 Neuromuscular Agents Phase 3,Phase 2,Not Applicable
33 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
34 onabotulinumtoxinA Phase 3,Phase 2,Not Applicable
35 Pharmaceutical Solutions Phase 3,Not Applicable,Early Phase 1
36 Phosphodiesterase 5 Inhibitors Phase 2, Phase 3,Phase 3,Not Applicable,Early Phase 1
37 Vardenafil Dihydrochloride Phase 2, Phase 3
38 calcium channel blockers Phase 3,Phase 2,Early Phase 1
39 Calcium, Dietary Phase 3,Phase 2,Early Phase 1,Not Applicable
40 Tocolytic Agents Phase 3,Early Phase 1
41 Sildenafil Citrate Phase 2, Phase 3,Phase 3,Early Phase 1 171599-83-0
42 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine Phase 3
43 Protein Kinase Inhibitors Phase 3
44 Anticoagulants Phase 3
45 Chelating Agents Phase 3
46 Anesthetics Phase 2, Phase 3,Not Applicable
47 Anesthetics, Local Phase 2, Phase 3
48 Central Nervous System Depressants Phase 2, Phase 3
49
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
50 Citrate Nutraceutical Phase 2, Phase 3,Phase 3,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 65)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048776 Phase 4 Pletal
2 Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048763 Phase 4 Pletal
3 Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms Unknown status NCT00934427 Phase 3 0.9% nitroglycerin in TAM cream;vehicle cream
4 A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon Unknown status NCT00577304 Phase 3 Nitroglycerin;Topical AmphiMatrix
5 Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome Completed NCT02165111 Phase 3 Onabotulinumtoxin A;sterile saline solution
6 Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's Syndrome Completed NCT01291199 Phase 2, Phase 3 vardenafil;Placebo
7 Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT00626665 Phase 3 Tadalafil
8 Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon Completed NCT00266669 Phase 3 Topical organogel with nitroglycerin
9 St. John's Wort in the Treatment of Raynaud's Phenomenon Completed NCT00351117 Phase 3 St. John's Wort;Lactose
10 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT00004786 Phase 3 iloprost
11 Lab Study of MQX-503 in Treatment of Raynaud's Completed NCT00253331 Phase 2, Phase 3 topical organogel with nitroglycerin
12 Raynaud's Treatment Study (RTS) Completed NCT00000530 Phase 3 nifedipine
13 Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon Completed NCT00419419 Phase 3 Topical AmphiMatrix with nitroglycerin (MQX-503)
14 "As Required" Oral Sildenafil in Raynaud's Phenomenon Completed NCT02050360 Phase 2, Phase 3 Sildenafil 40 mg;Sildenafil 80 mg;Placebo
15 Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon Completed NCT01280266 Phase 2, Phase 3 Udenafil or Amlodipine
16 A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon Completed NCT00498615 Phase 3 Fasudil
17 A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT01117298 Phase 3 Tadalafil;Placebo
18 Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis Completed NCT01347008 Phase 3 Sildenafil citrate;Placebo (Sugar pill)
19 A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis Completed NCT01532869 Phase 3 Placebo;tocilizumab [RoActemra/Actemra];tocilizumab [RoActemra/Actemra]
20 Exparel as a Nerve Block for Severe Hand Pain Terminated NCT02374320 Phase 2, Phase 3 liposomal bupivacaine
21 Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon Unknown status NCT02356809 Phase 1, Phase 2 Neovasculgen
22 Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease Completed NCT00528242 Phase 2 SLx-2101;Placebo
23 Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon Completed NCT00480753 Phase 2 Nitroglycerin
24 Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator Completed NCT01926847 Phase 2 Riociguat (Adempas, BAY63-2521);Placebo
25 Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon Completed NCT00378521 Phase 2 MQX-503
26 Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon Completed NCT00251238 Phase 2 Ginkgo biloba extract EGb 761
27 PF-00489791 For The Treatment Of Raynaud's Completed NCT01090492 Phase 2 PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791
28 Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT02228850 Phase 2 Alprostadil
29 Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon Completed NCT02688270 Phase 2 Vascana (0.9% nitroglycerin cream);Vehicle (placebo)
30 Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction Completed NCT00707187 Phase 2 Cialis
31 Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT02260557 Phase 2 Selexipag;Placebo
32 Brentuximab Vedotin for Systemic Sclerosis Recruiting NCT03222492 Phase 1, Phase 2
33 A Two-Part Study of BOTOX® Therapy for Ischemic Digits Active, not recruiting NCT01309802 Phase 2 onabotulinum toxin type-A
34 Riociguat in Scleroderma Associated Digital Ulcers Active, not recruiting NCT02915835 Phase 2 Riociguat;Placebo
35 Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH) Active, not recruiting NCT02290613 Phase 2 Ambrisentan;Placebo
36 Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon Terminated NCT01315899 Phase 2 ORM-12471 30mg;ORM-12471;placebo
37 Dose Response to Topical Glyceryl Trinitrate in Patients With Raynaud's Phenomenon Completed NCT00700518 Phase 1 placebo cream;Glyceryl Trinitrate;Glyceryl Trinitrate;Glyceryl Trinitrate;Glyceryl Trinitrate
38 MQX-503 Applied to the Hand Versus Nitroglycerin Ointment Applied to the Chest: A Pharmacokinetic Comparison Completed NCT00841594 Phase 1 nitroglycerin 0.9 % (MXQ-503);Nitroglycerin ointment 2%, USP
39 Prognostic Influence of Light Rheography Measurement of Patients With Secondary Raynaud Syndrome With Ulcers on Hands Unknown status NCT01378845 Not Applicable Tracleer;Prostavasin
40 PORH and Response to Cold in Raynaud's Phenomenon. Unknown status NCT02183779 Not Applicable L-NMMA and Fluconazole dermic injection
41 Psychopathology of Normal-tension Glaucoma in Hong Kong Chinese Out-patient Unknown status NCT00324181
42 Nova Cold Hands Raynaud's Disorder, a Disease Which Results in Decreased Blood Flow to the Hands and Feet. Completed NCT02615964
43 Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis Completed NCT02212249 Not Applicable
44 Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon Completed NCT02683408 Not Applicable
45 Botulinum Toxin in the Treatment of Raynaud's Completed NCT01233999 Not Applicable botulinum toxin A
46 Laser Speckle Contrast Imaging for Cutaneous Microvascular Dysfunction Detection in Systemic Sclerosis. Completed NCT01743612 Not Applicable
47 Tadalafil for the Treatment of Raynaud's Completed NCT00822354 Not Applicable Tadalafil
48 Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR) Completed NCT02396238 Not Applicable
49 Acupressure for the Treatment of Raynaud's Phenomenon Completed NCT01784354 Not Applicable
50 ADDICTAO: Psychological and Addictive Profile of Patients With Buerger's Disease Completed NCT01064206

Search NIH Clinical Center for Raynaud Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: raynaud disease

Sources

Genetic Tests for Raynaud Disease

About this section
Sources

Anatomical Context for Raynaud Disease

About this section

MalaCards organs/tissues related to Raynaud Disease:

41
Lung, Skin, Heart, Bone, Endothelial
Sources

Publications for Raynaud Disease

About this section

Articles related to Raynaud Disease:

# Title Authors Year
1
Raynaud disease. ( 24211176 )
2014
2
Intraoral telangiectasias associated with Raynaud disease: a report of two cases. ( 19907728 )
2010
3
Improvement in both Raynaud disease and hyperhidrosis in response to botulinum toxin type A treatment. ( 18627700 )
2008
4
Long-term effects of thoracic sympathectomy on microcirculation in the hands of patients with primary Raynaud disease. ( 17532934 )
2007
5
Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. ( 16432094 )
2006
6
Diabetes mellitus vs. Raynaud disease: different lung vascular bed disorders. ( 12505097 )
2002
7
Increased prevalence of migraine and chest pain in patients with primary Raynaud disease. ( 1586109 )
1992
8
Effect of indoramin on finger circulation in patients with Raynaud disease. ( 2423806 )
1986
9
Raynaud disease with oral manifestations. ( 1119826 )
1975
Sources

Variations for Raynaud Disease

About this section
Sources

Expression for Raynaud Disease

About this section
Search GEO for disease gene expression data for Raynaud Disease.
Sources

Pathways for Raynaud Disease

About this section

Pathways related to Raynaud Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Platelet Aggregation Inhibitor Pathway, Pharmacodynamics 61
10.86 PTGIR VWF
2
Endothelin Pathways 1
10.49 EDN1 PTGIR
3
Prostaglandin Synthesis and Regulation 1
10.1 EDN1 PTGIR
Sources

GO Terms for Raynaud Disease

About this section

Cellular components related to Raynaud Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Weibel-Palade body GO:0033093 8.62 EDN1 VWF
Sources

Sources for Raynaud Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....